奈达铂与紫杉醇（白蛋白结合型）化疗同步IMRT在颈段及胸上段食管癌中的疗效

打开文本图片集

Efficacy Nedaplatinand Paclitaxel （Albumin-bound Type） Chemotherapy Combined with Concurrent IMRT in Cervical and Upper Thoracic Esophageal Cancer/MAO Runzhi.

[Abstract] Objective： To analyze the effect Nedaplatin and Paclitaxel （Albumin-bound Type） chemotherapy combined with concurrent intensity-modulated radiotherapy （IMRT） in patients with cervical and upper thoracic esophageal cancer.Method： Sixty patients with cervical and upper thoracic esophageal cancer from QuanzhouFirst HospitalfromJanuary 2O21 to June2O23 were selectedas the research subjects.They were randomly divided into two groups based on a random number table method， with 30 patients in each group.The control group received IMRT， while the study group received Nedaplatin and Paclitaxel （Albumin-bound Type） chemotherapy combined with concurrent IMRTtreatment.The effcacy two different treatment regimens and the differences in serum tumor marker levels before and after treatment，as wellas the incidence adverse reactions during treatment andsurvival the two groups wereobserved.Result： Comparedwith thecontrolgroup，the effctiverateanddisease controlrate the study group were higher，theexpresson levels serum tumor markersone month after treatment in the study group were lower than those in the control group （ P <0.05）. There were no statistically significant differences in the incidences adverse reactions between the two groups （ Pγ >0.05）.The 1-year survival rate the

study group，the Karnsky performance status （KPS）score at one-year follow-up the surviving patients in the study group was higher than that in the control group （ P<0.05， .Conclusion： The treatment regimen Nedaplatin and Paclitaxel （Albumin-bound Type）chemotherapy combined with concurrent IMRTcan help improve the clinical efficacy patients with cervical and upper thoracic esophageal cancer，reduce the expression levels serum tumor markers，and help increase the 1-year survival rate patients.

[Keywords]Paclitaxel （Albumin-bound Type）Esophageal cancerIntensity modulated radiation therapy 'umor markers

First-author's address：Department Radiotherapy，Quanzhou First Hospital， Quanzhou 362000，

China

doi：10.3969/j.issn.1674-4985.2025.25.010

食管癌是当前临床常见病与多发病，随着中国内镜技术的不断进步与发展，越来越多食管癌患者被发现，疾病病理类型以鳞状细胞癌为主[-2]。（剩余6986字）